Comparative Pharmacology
Head-to-head clinical analysis: ADAPALENE versus AMNESTEEM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADAPALENE versus AMNESTEEM.
ADAPALENE vs AMNESTEEM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Retinoic acid receptor agonist; binds to RARβ/γ nuclear receptors, modulating gene expression to normalize follicular keratinization and reduce comedogenesis.
Retinoid that binds to and activates retinoic acid receptors (RARs), thereby normalizing keratinocyte differentiation and reducing sebum production.
Apply a pea-sized amount topically to affected areas once daily in the evening.
0.5-1.0 mg/kg/day orally in 2 divided doses
None Documented
None Documented
The terminal elimination half-life of adapalene after topical application is approximately 17 hours (range 7–51 hours), reflecting slow release from skin depot and hepatic clearance. This supports once-daily dosing.
Clinical Note
moderateAdapalene + Gatifloxacin
"Adapalene may increase the neuroexcitatory activities of Gatifloxacin."
Clinical Note
moderateAdapalene + Rosoxacin
"Adapalene may increase the neuroexcitatory activities of Rosoxacin."
Clinical Note
moderateAdapalene + Levofloxacin
"Adapalene may increase the neuroexcitatory activities of Levofloxacin."
Clinical Note
moderateAdapalene + Trovafloxacin
"Adapalene may increase the neuroexcitatory activities of Trovafloxacin."
Terminal elimination half-life: 10-20 hours (mean 17 hours) in patients with normal renal function; prolonged in severe renal impairment
Adapalene is eliminated primarily via biliary excretion into feces. After oral administration in animals, approximately 80% of the dose is recovered in feces and about 10% in urine; for topical application, systemic absorption is minimal and the small absorbed fraction undergoes similar hepatobiliary elimination.
Renal (65-83% as unchanged drug and metabolites), fecal (15-35% as metabolites)
Category D/X
Category C
Retinoid
Retinoid